Skip to main content

Post categories

  • Home
  • Contact Us
  • Login
  • Register
Home
  • INDUSTRY UPDATES
    • Packaging News
    • Innovations
    • Packaging Offers
    • Press Releases
    • Events
    • resources
  • BLOG
  • OUR PRODUCTS
    • Big Book of Packaging
  • OUR PARTNERS
    • Bernhardt
    • EMA
    • Haemotronic
    • Linhardt
    • Ypsomed
    • Plas-Tech Engineering
    • Roechling
    • Sanok Rubber
    • Schreiner
    • Polycine
    • Yukon Medical
    • Bonini
  • SERVICES
    • CONSULTING
    • DESIGN SERVICES

Breadcrumb

  1. Home
  2. Haselmeier signs an Exclusive Agreement with Stevanato Group to License Axis-D Pen-injector Technology and Intellectual Property for the Therapeutic Area of Diabetes Care

Haselmeier signs an Exclusive Agreement with Stevanato Group to License Axis-D Pen-injector Technology and Intellectual Property for the Therapeutic Area of Diabetes Care

Profile picture for user pr011
By pr011 on Thu, 10/31/2019 - 18:13

The Axis-D pen-injector was designed and developed by Haselmeier together with its partners, and a version of this pen-injector is currently on the market today having been launched by a major pharmaceutical company and approved for use, among others, by the European Medical Agency (EMA) and the US Food and Drug Administration (FDA). Stevanato Group plans to utilize this technology and IP to provide a new pen injector to support the needs of diabetes patients all over the world. Once the design for the device is finalized, it will be produced at one of Stevanato Group’s manufacturing facilities, based on extensive tooling and molding expertise. Sub-assembly and final assembly equipment will be provided by Stevanato Group operations in Denmark.

Frédéric Gabriel, Chief Innovation Officer at Haselmeier, said: “We are pleased and proud to have Stevanato Group as our strategic partner for Axis-D in Diabetes. Stevanato Group has demonstrated in past years a consistent development strategy coupled with unique integrated capabilities and is able to leverage Haselmeier’s pen injection platform to bring it to the next level. Such platform has already been proven in the market, from an IP, performance and user perspective. It also demonstrates Haselmeier’s strategic orientation to exploit its IP over various paths, either with own development and manufacturing capabilities or together with a strategic partner.”

“Consistent with its vision Stevanato Group always welcomes strategic agreements with key players in the market to broaden its global capabilities” said Paolo Patri, Chief Technology Officer at Stevanato Group. “We value our relationship with Haselmeier as a device technology partner. With this agreement, we continue to expand our portfolio of devices for patients suffering from diabetes. This complements ongoing work on our award winning 1ml cartridge-based wearable device, which will give our biopharmaceutical partners the opportunity to provide patients with both standard and alternative treatment solutions with such devices.”

https://haselmeier.com/en/news/

Follow Us

  • linkedin
  • facebook-f
  • twitter

Explore

  • Home
  • Contact Us
  • Login
  • Register

Company

  • Archive
  • Blog
  • Events
  • Packaging News
Autentico develops Anti-Counterfeit Packaging !
20 Mar, 2023
Standardized packaging on vapes found to reduce appeal to teenagers
20 Mar, 2023
Freppel Imprimeur Invests in Asahi CleanPrint AWP™ Water-Washable Plates
19 Mar, 2023

Footer menu

  • Privacy
  • Terms and conditions
Home
  • INDUSTRY UPDATES
    • Packaging News
    • Innovations
    • Packaging Offers
    • Press Releases
    • Events
    • resources
  • BLOG
  • OUR PRODUCTS
    • Big Book of Packaging
  • OUR PARTNERS
    • Bernhardt
    • EMA
    • Haemotronic
    • Linhardt
    • Ypsomed
    • Plas-Tech Engineering
    • Roechling
    • Sanok Rubber
    • Schreiner
    • Polycine
    • Yukon Medical
    • Bonini
  • SERVICES
    • CONSULTING
    • DESIGN SERVICES
Clear keys input element